Buscar
Cellectis SA
CLLSAñadir a la lista de seguimiento
3.300USD
+0.360+12.24%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
238.67MCap. mercado
PérdidaP/E TTM
Más Datos de Cellectis SA Compañía
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Información de Cellectis SA
Símbolo de cotizaciónCLLS
Nombre de la empresaCellectis SA
Fecha de salida a bolsaFeb 06, 2007
Director ejecutivoSourdive (David J.D)
Número de empleados224
Tipo de seguridadDepository Receipt
Fin del año fiscalFeb 06
Dirección8, rue de la Croix Jarry
CiudadPARIS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísFrance
Código postal75013
Teléfono33181691600
Sitio Webhttps://www.cellectis.com/
Símbolo de cotizaciónCLLS
Fecha de salida a bolsaFeb 06, 2007
Director ejecutivoSourdive (David J.D)
Ejecutivos de Cellectis SA
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Dr. David Sourdive, Ph.D.
Dr. David Sourdive, Ph.D.
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Pierre Bastid
Mr. Pierre Bastid
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Laurent Arthaud
Mr. Laurent Arthaud
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Rainer J. Boehm, M.D.
Dr. Rainer J. Boehm, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Stephan Reynier
Mr. Stephan Reynier
Chief Regulatory and Pharmaceutical Compliance Officer
Chief Regulatory and Pharmaceutical Compliance Officer
--
--
Ms. Marie-Bleuenn Terrier
Ms. Marie-Bleuenn Terrier
General Counsel
General Counsel
--
--
Mr. Arthur Stril
Mr. Arthur Stril
Chief Financial Officer and Chief Business Officer
Chief Financial Officer and Chief Business Officer
--
--
Dr. Steven (Steve) Doares, Ph.D.
Dr. Steven (Steve) Doares, Ph.D.
Senior Vice President - US Manufacturing
Senior Vice President - US Manufacturing
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Dr. David Sourdive, Ph.D.
Dr. David Sourdive, Ph.D.
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Pierre Bastid
Mr. Pierre Bastid
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Laurent Arthaud
Mr. Laurent Arthaud
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Rainer J. Boehm, M.D.
Dr. Rainer J. Boehm, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Cellectis SA?
Los cinco principales accionistas de Cellectis SA son: Dr. Andre Choulika, Ph.D.
¿Cuántas instituciones poseen acciones de Cellectis SA (CLLS)?
A fecha de 2026Q1, 77 instituciones poseen acciones de Cellectis SA, con un valor de mercado combinado de aproximadamente 12.30M, lo que representa el 17.00% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -5544701.00.